However, when we assessed the relationship of OS and syndecan-1 level, there was a significant difference in the median OS of studied AML cases when we compared the OS at low plasma level of syndecan-1 (14 months) and high plasma level (four months; p = 0.044; Figure 2). The gene discussed is SDC1; the disease is acute myeloid leukemia.